Article
Urology & Nephrology
Christopher Yanucil, Dominik Kentrup, Isaac Campos, Brian Czaya, Kylie Heitman, David Westbrook, Gunars Osis, Alexander Grabner, Adam R. Wende, Julian Vallejo, Michael J. Wacker, Jose Alberto Navarro-Garcia, Gema Ruiz-Hurtado, Fuming Zhang, Yuefan Song, Robert J. Linhardt, Kenneth White, Michael S. Kapiloff, Christian Faul
Summary: Fibroblast growth factor (FGF) 23 is an elevated phosphate-regulating hormone in patients with chronic kidney disease and associated with cardiovascular mortality. This study found that soluble klotho and heparin regulate FGF23 signaling and effects in cardiac myocytes, with opposite effects.
KIDNEY INTERNATIONAL
(2022)
Article
Cardiac & Cardiovascular Systems
Katharina Doerr, Michael Kammer, Roman Reindl-Schwaighofer, Matthias Lorenz, Thomas Prikoszovich, Rodrig Marculescu, Dietrich Beitzke, Alice Wielandner, Reinhold G. Erben, Rainer Oberbauer
Summary: The study aimed to investigate the effect of FGF23 suppression by calcimimetic therapy on LVH progression in patients with chronic kidney disease. The results showed that etelcalcetide treatment inhibited the progression of LVH compared to alfacalcidol, potentially reducing the risk of sudden cardiac death in this population.
CIRCULATION RESEARCH
(2021)
Article
Agriculture, Dairy & Animal Science
Jiakun Yan, Chong Pan, Yanli Liu, Xujie Liao, Jionghao Chen, Yufei Zhu, Xinhuo Huang, Xiaojun Yang, Zhouzheng Ren
Summary: The present study evaluated the effects of dietary supplemental vitamin D-3 on fibroblast growth factor 23 (FGF23) signals, phosphorus homeostasis, and metabolism in laying hens. The results showed that restriction of dietary vitamin D-3 reduced serum phosphorus levels in laying hens and suppressed the expression of FGF23 signaling-related genes.
Review
Endocrinology & Metabolism
Pan-Pan Hu, Jing-Fu Bao, Aiqing Li
Summary: The fibroblast growth factor-23-alpha-Klotho axis is closely related to chronic kidney disease and has multiple biological functions beyond bone-mineral metabolism. Dysregulation of this axis has been observed in acute kidney injury, but its exact role in the pathophysiology of acute kidney injury remains largely unknown. It may provide new therapeutic targets for treating acute kidney injury.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Cell Biology
Baris Afsar, Mehmet Kanbay, Rengin Elsurer Afsar
Summary: Bone marrow hematopoiesis is regulated by various factors, including bone components, EPO, and FGF23. The interaction between these factors involves HIF pathway, direct stimulation of FGF23 synthesis, and cleavage of FGF23. Recent evidence suggests a complex relationship between FGF23, klotho, EPO, and HIF in hematopoiesis.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Evangelos Memmos, Aikaterini Papagianni
Summary: Changes in FGF-23 and Klotho levels are considered to be the earliest biochemical abnormality of CKD-MBD syndrome and have significant effects on the cardiovascular system, contributing to increased CV morbidity and mortality rates in CKD patients. Further research is needed to understand their role as cardiovascular risk factors.
CURRENT VASCULAR PHARMACOLOGY
(2021)
Article
Neurosciences
Stan R. Ursem, Charlene Diepenbroek, Vesna Bacic, Unga A. Unmehopa, Leslie Eggels, Clarissa M. Maya-Monteiro, Annemieke C. Heijboer, Susanne E. la Fleur
Summary: FGF23, an endocrine growth factor, plays a pivotal role in phosphate homeostasis. Research has shown the presence of FGF23 and alpha Klotho protein in the hypothalamus, suggesting a potential role for FGF23 in the brain. However, gene expression of FGF23 was not detected in the brain, indicating that the observed FGF23 protein may not be brain-derived.
EUROPEAN JOURNAL OF NEUROSCIENCE
(2021)
Article
Cell Biology
Maren Leifheit-Nestler, Miriam A. Wagner, Beatrice Richter, Corinna Piepert, Fiona Eitner, Ineke Boeckmann, Isabel Vogt, Andrea Grund, Susanne S. Hille, Ariana Foinquinos, Karina Zimmer, Thomas Thum, Oliver J. Mueller, Dieter Haffner
Summary: Through experiments using a mouse model with high intra-cardiac Fgf23 synthesis, it was found that chronic exposure to elevated cardiac iFgf23 does not induce LVH in healthy mice, suggesting that Fgf23 excess per se does not affect the heart.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Medicine, General & Internal
Hyo Jin Kim, Yunmi Kim, Minjung Kang, Seonmi Kim, Sue Kyung Park, Suah Sung, Young Youl Hyun, Ji Yong Jung, Curie Ahn, Kook-Hwan Oh
Summary: This study evaluated the impact of the soluble Klotho and circulating FGF23 ratio on the risk of renal progression, cardiovascular events, and mortality in CKD. The results indicated that a low Klotho/FGF23 ratio was associated with an increased risk of renal events.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, Research & Experimental
Tomohiro Saito, Masahide Mizobuchi, Tadashi Kato, Hiroaki Ogata, Fumihiko Koiwa, Hirokazu Honda
Summary: This study investigated the effect of continuous intravenous (CIV) FGF23 loading on cardiac function in a mouse model of mild chronic kidney disease and hypertension with heart failure. The results showed that CIV FGF23 loading exacerbated cardiac fibrosis, and abnormal vitamin D metabolism was involved in this mechanism. Calcitriol attenuated this exacerbation by mediating transforming growth factor-13 signaling independently of the FGF23 levels.
LABORATORY INVESTIGATION
(2023)
Review
Urology & Nephrology
S. Madison Thomas, Qing Li, Christian Faul
Summary: This article discusses the physiological and pathological effects of fibroblast growth factor (FGF) 23, focusing on its receptors and co-receptors. Recent studies have shown that Klotho acts as a co-receptor for FGF23, and soluble klotho (sKL) and heparan sulfate (HS) have emerged as circulating co-receptors for FGFR that modulate the actions of FGF23. Experimental studies suggest that sKL protects against CKD-associated heart injury, while HS accelerates it. However, the relevance of these findings in vivo is still speculative.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
(2023)
Review
Medicine, General & Internal
Javier Donate-Correa, Ernesto Martin-Nunez, Ainhoa Gonzalez-Luis, Carla M. Ferri, Desiree Luis-Rodriguez, Victor G. Tagua, Carmen Mora-Fernandez, Juan E. Navarro-Gonzalez
Summary: Observational studies have linked the increase in FGF23 levels with the onset of diabetes, suggesting the existence of potential diabetogenic mechanisms originating from chronic supraphysiological levels of FGF23 in CKD and ESRD patients. These mechanisms could involve direct and indirect effects on pancreatic ss cells, as well as the stimulation of pro-inflammatory factors synthesis, potentially mediated by the binding of FGF23 to noncanonical receptor complexes.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Ting-Wei Lee, Cheng-Chih Chung, Ting- Lee, Yung-Kuo Lin, Yu-Hsun Kao, Yi-Jen Chen
Summary: This study found that FGF-23 can promote the proliferation and migration abilities of cardiac fibroblasts, leading to excessive entry of Ca2+ and increased IP3 levels. In addition, FGF-23 can increase the expression levels of calcium release-activated calcium channel protein 1 and transient receptor potential canonical 1 channel. The study also found that FGF-23 regulates cardiac fibroblast activity by activating FGF receptor 1 and the phospholipase C/IP3 signaling pathway.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Giuliano da Paz Oliveira, Rosilene Motta Elias, Gustavo Bruniera Peres Fernandes, Rosa Moyses, Sergio Tufik, Denis Bernardi Bichuetti, Fernando Morgadinho Santos Coelho
Summary: The study found that patients with narcolepsy have decreased CSF concentration of klotho and increased CSF levels of FGF-23, which may play a role in understanding the pathogenesis of narcolepsy.
Article
Multidisciplinary Sciences
Christopher Yanucil, Dominik Kentrup, Xueyi Li, Alexander Grabner, Karla Schramm, Eliana C. Martinez, Jinliang Li, Isaac Campos, Brian Czaya, Kylie Heitman, David Westbrook, Adam R. Wende, Alexis Sloan, Johanna M. Roche, Alessia Fornoni, Michael S. Kapiloff, Christian Faul
Summary: FGF21 targets cardiac myocytes to induce concentric hypertrophy, which may be a novel mechanism for heart failure in type 2 diabetes patients. Short-term elevation of FGF21 can be cardio-protective, but prolonged elevation may have adverse effects.
SCIENTIFIC REPORTS
(2022)
Review
Endocrinology & Metabolism
Pan-Pan Hu, Jing-Fu Bao, Aiqing Li
Summary: The fibroblast growth factor-23-alpha-Klotho axis is closely related to chronic kidney disease and has multiple biological functions beyond bone-mineral metabolism. Dysregulation of this axis has been observed in acute kidney injury, but its exact role in the pathophysiology of acute kidney injury remains largely unknown. It may provide new therapeutic targets for treating acute kidney injury.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Medicine, Research & Experimental
Jingfu Bao, Yinghui Lu, Qinying She, Weijuan Dou, Rong Tang, Xiaodong Xu, Mingchao Zhang, Ling Zhu, Qing Zhou, Hui Li, Guohua Zhou, Zhongzhou Yang, Shaolin Shi, Zhihong Liu, Chunxia Zheng
Summary: In CKD rats, restoration of cardiomyocyte-specific miRNA-30 helps to alleviate LVH, while blockade of miRNA-30 leads to cardiomyocyte hypertrophy. CKD-related factors suppress cardiac miRNA-30 expression, while supplementation of miRNA-30 mitigates cardiomyocyte hypertrophy induced by these factors.
Article
Oncology
Yifan Wang, Xin Wang, Huizhen Wang, Jingfu Bao, Nan Jia, Huimi Huang, Aiqing Li
Summary: PTEN plays a renoprotective role in ischemia-reperfusion injury, alleviating apoptosis and improving autophagy through the PI3K/Akt/mTOR and PI3K/Akt/HIF1-alpha pathways.
EXPERIMENTAL CELL RESEARCH
(2021)
Review
Endocrinology & Metabolism
Qin-Ying She, Jing-Fu Bao, Hui-Zhen Wang, Huixin Liang, Wentao Huang, Jing Wu, Yiwen Zhong, Hanxin Ling, Aiqing Li, Shu-Lan Qin
Summary: This article summarizes the important roles of fibroblast growth factor 21 in metabolic homeostasis and highlights its pharmacological potential in mitigating metabolic disorders. However, the current clinical trials have not achieved the desired results, raising questions about its clinical value.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2022)
Article
Cell Biology
Huizhen Wang, Yifan Wang, Xin Wang, Huimi Huang, Jingfu Bao, Wenhui Zhong, Aiqing Li
Summary: PTEN plays a crucial role in renal adaptive repair by upregulating CHMP2A to alleviate cell damage, apoptosis, and renal fibrosis. PTEN overexpression promotes phagosome closure, providing a potential therapeutic target for the transition from AKI to CKD.
CELL DEATH & DISEASE
(2021)
Letter
Geriatrics & Gerontology
Jing-Fu Bao, Pan-Pan Hu, Aiqing Li
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Article
Cardiac & Cardiovascular Systems
Jing-Fu Bao, Pan-Pan Hu, Qin-Ying She, Difei Zhang, Jia-Ju Mo, Aiqing Li
Summary: This study evaluates the state of research on uremic cardiomyopathy in the past 30 years through bibliometric analysis. The findings reveal slower progress in recent years, with the United States as the most productive and cited country. The research highlights phosphate metabolism as a recent hotspot, while endogenous natriuretic factors and novel biomarkers may be potential directions for future investigations.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Endocrinology & Metabolism
Jing-Fu Bao, Qin-Ying She, Pan-Pan Hu, Nan Jia, Aiqing Li
Summary: Irisin, generated by cleavage of membrane protein FNDC-5, is a muscle-secreted hormone that is believed to have therapeutic effects on metabolic and non-metabolic diseases, especially in relation to exercise regulation. However, there are controversies surrounding its functions, requiring further research and exploration.
TRENDS IN ENDOCRINOLOGY AND METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Qin-Ying She, Li-Juan Li, Ming-Hong Liu, Ru-Yu Tan, Yi-Wen Zhong, Jing-Fu Bao, Jie-Dong Xie
Summary: This study used bibliometric analysis to evaluate the state and future directions of FGF-21 research over the past 20 years. The results showed that the peripheral metabolic effects of FGF-21, FGF-21-based drug development, and translational research on metabolic diseases were the major topics of research. The emerging trends were the central metabolic effects of FGF-21 and the effects of FGF-21 on non-metabolic diseases.
FRONTIERS IN PHARMACOLOGY
(2022)
